DT-216
DTX-216-102
Phase 1 small_molecule completed
Quick answer
DT-216 for Friedreich Ataxia is a Phase 1 program (small_molecule) at Lxo Ireland Designated Activity Company with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Lxo Ireland Designated Activity Company
- Indication
- Friedreich Ataxia
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed